Alnylam Pharmaceuticals (ALNY) Cash & Equivalents (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Cash & Equivalents data on file, last reported at $1.7 billion in Q2 2026.

• Quarterly Cash & Equivalents rose 53.39% year-over-year to $1.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 53.39% YoY) and the FY2025 annual result came in at $1.7 billion, up 71.09% from the prior year.
• Cash & Equivalents steadied at $1.7 billion in Q2 2026, from $1.7 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.7 billion in Q1 2026 to a low of $534.1 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $994.2 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents dropped 22.82% — and 2025, when it jumped 71.09%.
• Tracing ALNY's Cash & Equivalents over 5 years: stood at $868.6 million in 2022, then retreated by 6.43% to $812.7 million in 2023, then climbed by 19.19% to $968.7 million in 2024, then jumped by 71.09% to $1.7 billion in 2025, then grew by 3.08% to $1.7 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.7 billion (Q2 2026), $1.7 billion (Q1 2026), and $1.7 billion (Q4 2025), per Business Quant data.